| Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties SM Moghimi, J Szebeni Progress in lipid research 42 (6), 463-478, 2003 | 1602 | 2003 |
| Complement activation-related pseudoallergy: a new class of drug-induced acute immune toxicity J Szebeni Toxicology 216 (2-3), 106-121, 2005 | 693 | 2005 |
| Complement activation following first exposure to pegylated liposomal doxorubicin (Doxil®): possible role in hypersensitivity reactions A Chanan-Khan, J Szebeni, S Savay, L Liebes, NM Rafique, CR Alving, ... Annals of Oncology 14 (9), 1430-1437, 2003 | 543 | 2003 |
| Activation of complement by therapeutic liposomes and other lipid excipient-based therapeutic products: prediction and prevention J Szebeni, F Muggia, A Gabizon, Y Barenholz Advanced drug delivery reviews 63 (12), 1020-1030, 2011 | 486 | 2011 |
| Complement Activation by Cremophor EL as a Possible Contributor to Hypersensitivity to Paclitaxel: an In Vitro Study J Szebeni, CR Alving, FM Muggia JNCI: Journal of the National Cancer Institute 90 (4), 300-306, 1998 | 420 | 1998 |
| Complement activation-related pseudoallergy: a stress reaction in blood triggered by nanomedicines and biologicals J Szebeni Molecular immunology 61 (2), 163-173, 2014 | 409 | 2014 |
| Anti-PEG antibodies: Properties, formation, testing and role in adverse immune reactions to PEGylated nano-biopharmaceuticals GT Kozma, T Shimizu, T Ishida, J Szebeni Advanced drug delivery reviews 154, 163-175, 2020 | 378 | 2020 |
| PEGylated liposomes: immunological responses M Mohamed, AS Abu Lila, T Shimizu, E Alaaeldin, A Hussein, HA Sarhan, ... Science and Technology of Advanced Materials 20 (1), 710-724, 2019 | 375 | 2019 |
| Hypersensitivity reactions to intravenous iron: guidance for risk minimization and management D Rampton, J Folkersen, S Fishbane, M Hedenus, S Howaldt, F Locatelli, ... haematologica 99 (11), 1671, 2014 | 312 | 2014 |
| F(ab)′2-mediated neutralization of C3a and C5a anaphylatoxins: a novel effector function of immunoglobulins M Basta, F Van Goor, S Luccioli, EM Billings, AO Vortmeyer, L Baranyi, ... Nature medicine 9 (4), 431-438, 2003 | 293 | 2003 |
| Poly (ethylene glycol) s generate complement activation products in human serum through increased alternative pathway turnover and a MASP-2-dependent process I Hamad, AC Hunter, J Szebeni, SM Moghimi Molecular immunology 46 (2), 225-232, 2008 | 290 | 2008 |
| Complement activation by polyethoxylated pharmaceutical surfactants: Cremophor-EL, Tween-80 and Tween-20 Z Weiszhár, J Czúcz, C Révész, L Rosivall, J Szebeni, Z Rozsnyay European journal of pharmaceutical sciences 45 (4), 492-498, 2012 | 262 | 2012 |
| Liposome-induced complement activation and related cardiopulmonary distress in pigs: factors promoting reactogenicity of Doxil and AmBisome J Szebeni, P Bedőcs, Z Rozsnyay, Z Weiszhár, R Urbanics, L Rosivall, ... Nanomedicine: Nanotechnology, Biology and Medicine 8 (2), 176-184, 2012 | 256 | 2012 |
| Role of complement activation in hypersensitivity reactions to doxil and hynic PEG liposomes: experimental and clinical studies J Szebeni, L Baranyi, S Savay, J Milosevits, R Bunger, P Laverman, ... Journal of liposome research 12 (1-2), 165-172, 2002 | 245 | 2002 |
| Hemodynamic changes induced by liposomes and liposome-encapsulated hemoglobin in pigs: a model for pseudoallergic cardiopulmonary reactions to liposomes: role of complement and … J Szebeni, JL Fontana, NM Wassef, PD Mongan, DS Morse, DE Dobbins, ... Circulation 99 (17), 2302-2309, 1999 | 233 | 1999 |
| Animal models of complement-mediated hypersensitivity reactions to liposomes and other lipid-based nanoparticles J Szebeni, CR Alving, L Rosivall, R Bünger, L Baranyi, P Bedöcs, M Tóth, ... Journal of liposome research 17 (2), 107-117, 2007 | 231 | 2007 |
| Methylation of the phosphate oxygen moiety of phospholipid‐methoxy (polyethylene glycol) conjugate prevents PEGylated liposome‐mediated complement activation and anaphylatoxin … S Moein Moghimi, I Hamad, TL Andresen, K Jørgensen, J Szebeni, ... The FASEB journal 20 (14), 2591-2593, 2006 | 228 | 2006 |
| Liposome-induced pulmonary hypertension: properties and mechanism of a complement-mediated pseudoallergic reaction J Szebeni, L Baranyi, S Savay, M Bodo, DS Morse, M Basta, GL Stahl, ... American Journal of Physiology-Heart and Circulatory Physiology 279 (3 …, 2000 | 220 | 2000 |
| To PEGylate or not to PEGylate: Immunological properties of nanomedicine’s most popular component, polyethylene glycol and its alternatives D Shi, D Beasock, A Fessler, J Szebeni, JY Ljubimova, KA Afonin, ... Advanced drug delivery reviews 180, 114079, 2022 | 202 | 2022 |
| Complement activation-related pseudoallergy caused by liposomes, micellar carriers of intravenous drugs, and radiocontrast agents J Szebeni Critical Reviews™ in Therapeutic Drug Carrier Systems 18 (6), 2001 | 202 | 2001 |
yechezkel barenholzhebrew university of jerusalemEmail verificata su ekmd.huji.ac.il
